Abstract
Outcomes for patients with metastatic and recurrent osteosarcoma remain poor and a better understanding of the biology of this malignancy is critical to the development of prognostic biomarkers and novel therapies. The purpose of this study was to establish a biobank of osteosarcoma which has the potential of monitoring tumors dynamically with exosomes, to facilitate clinical and basic scientific research. The osteosarcoma biological specimen and clinical data of osteosarcoma were collected in Ruijin Hospital in two stages. In the first stage (2015–2017), the collection of tissue specimens and blood samples were performed at diagnostic biopsy, definitive surgery, recurrence and lung metastasis, according to the Children’s Oncology Group protocol. In the second stage (2017–2019), the tissue specimens were collected the same as before, but the blood samples were collected at the beginning of each MAP-I (methotrexate, cisplatin, doxorubicin, ifosfamide) chemotherapy cycle, and every 6 months after the last chemotherapy up to 3 years, according to our modified protocol, to dynamically monitor the status of possible alteration of gene expression profiling in the osteosarcoma. A total of 268 patients with osteosarcoma were enrolled in this study, 161 were men and 107 were women, with the mean age of 24.51 ± 15.58 years. Local recurrence occurred in 29 patients and lung metastasis in 51. The numbers of tissue and blood specimens reached 360 and 1023, respectively. 11 specimens were from recurrent osteosarcoma and 25 were from lung metastasis. The corresponding clinical and demographic data were collected in our electronic database. The osteosarcoma biobank built with our modified protocol mentioned above has the potential of monitoring tumors dynamically with exosomes and could provide specimens to the researches improving the biological understanding and outcome of this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aibaidula A, Lu JF, Wu JS, Zou HJ, Chen H, Wang YQ, Qin ZY, Yao Y, Gong Y, Che XM, Zhong P, Li SQ, Bao WM, Mao Y, Zhou LF (2015) Establishment and maintenance of a standardized glioma tissue bank: Huashan experience. Cell Tissue Bank 16 (2):271–281. https://doi.org/10.1007/s10561-014-9459-4
Bao Q, Gong L, Wang J, Wen J, Shen Y, Zhang W (2018) Extracellular vesicle RNA sequencing reveals dramatic transcriptomic alterations between metastatic and primary osteosarcoma in a liquid biopsy approach. Ann Surg Oncol 25 (9):2642–2651. https://doi.org/10.1245/s10434-018-6642-z
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2):281–297. https://doi.org/10.1016/s0092-8674(04)00045-5
Bone sarcomas (2014) ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3:iii113–123. https://doi.org/10.1093/annonc/mdu256
Borinstein SC, Beeler N, Block JJ, Gorlick R, Grohar P, Jedlicka P, Krailo M, Morris C, Phillips S, Siegal GP, Lawlor ER, Lessnick SL (2013) A decade in banking ewing sarcoma: a report from the children's oncology group. Front Oncol 3:57. https://doi.org/10.3389/fonc.2013.00057
Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Laboratory investigation. J Tech Methods Pathol 80 (12):1943–1949
Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu F, Yu P (2015) Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. Tumour Biol 36 (12):9873–9883. https://doi.org/10.1007/s13277-015-3751-1
Ferrari S, Serra M (2015) An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother 16 (18):2727–2736. https://doi.org/10.1517/14656566.2015.1102226
Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G (2005) Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23 (34):8845–8852. https://doi.org/10.1200/jco.2004.00.5785
Fujiwara T, Uotani K, Yoshida A, Morita T, Nezu Y, Kobayashi E, Yoshida A, Uehara T, Omori T, Sugiu K, Komatsubara T, Takeda K, Kunisada T, Kawamura M, Kawai A, Ochiya T, Ozaki T (2017) Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma. Oncotarget 8 (20):33375–33392. https://doi.org/10.18632/oncotarget.16498
Glover J, Krailo M, Tello T, Marina N, Janeway K, Barkauskas D, Fan TM, Gorlick R, Khanna C (2015) A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. Pediatr Blood Cancer 62 (3):450–455. https://doi.org/10.1002/pbc.25346
Glover J, Man TK, Barkauskas DA, Hall D, Tello T, Sullivan MB, Gorlick R, Janeway K, Grier H, Lau C, Toretsky JA, Borinstein SC, Khanna C, Fan TM (2017) Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: a report from the Children's Oncology Group and the QuadW Foundation. PLoS ONE 12 (7):e0181204
Gong L, Bao Q, Hu C, Wang J, Zhou Q, Wei L, Tong L, Zhang W, Shen Y (2018) Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1. Biochem Biophys Res Commun 500 (2):170–176. https://doi.org/10.1016/j.bbrc.2018.04.016
Guenther LM, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, Guo D, Sridharan M, London WB, Grier HE, Ecklund K, Janeway KA (2018) Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer 65: 4
He C, Xiong J, Xu X, Lu W, Liu L, Xiao D, Wang D (2009) Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 388 (1):35–40
Hu C, Chen X, Wen J, Gong L, Liu Z, Wang J, Liang J, Hu F, Zhou Q, Wei L, Shen Y, Zhang W (2017a) Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci 108 (7):1347–1356. https://doi.org/10.1111/cas.13256
Hu C, Wen J, Gong L, Chen X, Wang J, Hu F, Zhou Q, Liang J, Wei L, Shen Y, Zhang W (2017b) Thrombospondin-1 promotes cell migration, invasion and lung metastasis of osteosarcoma through FAK dependent pathway. Oncotarget 8 (44):75881–75892. https://doi.org/10.18632/oncotarget.17427
Jelinek JS, Murphey MD, Welker JA, Henshaw RM, Kransdorf MJ, Shmookler BM, Malawer MM (2002) Diagnosis of primary bone tumors with image-guided percutaneous biopsy: experience with 110 tumors. Radiology 223 (3):731–737. https://doi.org/10.1148/radiol.2233011050
Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, Jundt G, Kabisch H, Reichardt P, Jürgens H, Gadner H, Bielack SS (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21 (10):2011–2018. https://doi.org/10.1200/jco.2003.08.132
Kansara M, Teng MW, Smyth MJ, Thomas DM (2014) Translational biology of osteosarcoma. Nat Rev Cancer 14 (11):722–735. https://doi.org/10.1038/nrc3838
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141 (5):672–675. https://doi.org/10.1111/j.1365-2141.2008.07077.x
Lou JJ, Mirsadraei L, Sanchez DE, Wilson RW, Shabihkhani M, Lucey GM, Wei B, Singer EJ, Mareninov S, Yong WH (2014) A review of room temperature storage of biospecimen tissue and nucleic acids for anatomic pathology laboratories and biorepositories. Clin Biochem 47 (4–5):267–273. https://doi.org/10.1016/j.clinbiochem.2013.12.011
Majidzadeh AK, Kaviani A, Esmaeili R, Farahmand L, Shojamoradi MH, Zare AA, Eini L, Abbasvandi F, Olfatbakhsh A, Moazen H (2013) Iranian Breast Cancer Bio-Bank: the activity and challenging issues. Cell Tissue Bank 14 (1):11–20. https://doi.org/10.1007/s10561-012-9293-5
Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115 (7):1531–1543. https://doi.org/10.1002/cncr.24121
Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152:3–13. https://doi.org/10.1007/978-1-4419-0284-9_1
Rodríguez A, Vaneechoutte M (2019) Comparison of the efficiency of different cell lysis methods and different commercial methods for RNA extraction from Candida albicans stored in RNAlater. BMC Microbiol 19 (1):94. https://doi.org/10.1186/s12866-019-1473-z
San Lucas FA, Allenson K, Bernard V, Castillo J, Kim DU, Ellis K, Ehli EA, Davies GE, Petersen JL, Li D, Wolff R, Katz M, Varadhachary G, Wistuba I, Maitra A, Alvarez H (2016) Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol 27 (4):635–641. https://doi.org/10.1093/annonc/mdv604
Schwarzenbach H, Nishida N, Calin GA, Pantel K (2014) Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11 (3):145–156. https://doi.org/10.1038/nrclinonc.2014.5
Tang YT, Huang YY, Zheng L, Qin SH, Xu XP, An TX, Xu Y, Wu YS, Hu XM, Ping BH, Wang Q (2017) Comparison of isolation methods of exosomes and exosomal RNA from cell culture medium and serum. Int J Mol Med 40 (3):834–844. https://doi.org/10.3892/ijmm.2017.3080
Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159 (6):2249–2256
Wang J, Hu C, Wang J, Shen Y, Bao Q, He F, Wang H, Gong L, Liu Z, Hu F, Liang J, Zhou Q, Wei L, Wen J, Zhang W (1997) Checkpoint blockade in combination with doxorubicin augments tumor cell apoptosis in osteosarcoma. J Immunother (Hagerstown, Md: 1997) 42 (9):321–330. https://doi.org/10.1097/cji.0000000000000281
Xu JF, Wang YP, Zhang SJ, Chen Y, Gu HF, Dou XF, Xia B, Bi Q, Fan SW (2017) Exosomes containing differential expression of microRNA and mRNA in osteosarcoma that can predict response to chemotherapy. Oncotarget 8 (44):75968–75978. https://doi.org/10.18632/oncotarget.18373
Acknowledgements
This research was supported by the Grants of the National Natural Science Foundation of China (No.81773298; No.81702661), Grant of Shanghai Municipal Commission of Health and Family Planning (No. 20164Y0143; No. 201740139), and Grant of 2017 Science and Technology Innovation Plan of Shanghai (No. 17411951900).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zang, S., Wang, J., Wen, J. et al. Establishment of a dynamic osteosarcoma biobank: Ruijin experience. Cell Tissue Bank 21, 447–455 (2020). https://doi.org/10.1007/s10561-020-09831-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10561-020-09831-6